Sagent Pharmaceuticals Launches Dextrose Injection In Premix Ready-to-Use IV Bags

Sagent Pharmaceuticals has launched ondansetron in 5% dextrose injection in premix bags. Its an antiemetic and selective 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by chemotherapy.

Sagent’s ondansetron in 5% dextrose injection in premix bags, is the generic equivalent of GlaxoSmithKline’s Zofran Injection Premixed.

The company will begin marketing and shipping of ondansetron in 5% dextrose injection premix bags immediately.

Jeffrey Yordon, founder, chairman and chief executive officer, Sagent, said: Ondansetron premix is an important addition to our rapidly growing line of ready-to-use products. Our ondansetron premix bag provides healthcare workers with enhanced packaging features to aid in rapid and accurate product identification and administration.

Sagent will offer ondansetron in 5% dextrose injection in 32mg per 50ml single dose premix bags.